TABLE 1.
Demographic, Clinical, and Laboratory Characteristics of Patients With ENT-AAV, Non–ENT-AAV, and CRS
| ENT-AAV (n = 20) | Non–ENT-AAV (n = 24) | p value | CRS (n = 27) | p value | |
|---|---|---|---|---|---|
| Age, y | 53.0 (26.7–61.0) | 63.5 (52.2–71.0) | 0.0214 | 56.0 (38.0–68.0) | NS |
| Female, n (%) | 11 (55.0) | 13 (54.2) | NS | 11 (40.7) | NS |
| Disease duration (IQR), mo | 49.5 (6–196) | 68.0 (6–248) | NS | — | — |
| Organ involvement, n (%) | — | — | |||
| Systemic | 12 (60.0) | 17 (70.8) | NS | ||
| Lung | 11 (55.0) | 15 (62.5) | NS | ||
| Skin | 4 (20.0) | 8 (33.3) | NS | ||
| Eye | 3 (15.0) | 3 (12.5) | NS | ||
| Cardiovascular | 0 (0) | 1 (4.2) | NS | ||
| Abdominal | 4 (20.0) | 2 (8.3) | NS | ||
| Renal | 4 (20.0) | 16 (66.7) | 0.0027 | ||
| Nervous | 6 (30.0) | 12 (50.0) | NS | ||
| ANCA positivity, n (%) | 16 (80.0) | 24 (100) | — | — | |
| ANCA PR3 | 15 (93.7) | 13 (54.2) | 0.0357 | ||
| ANCA MPO | 1 (6.3) | 11 (45.8) | |||
| BVAS v3 | 0 (0–10) | 0 (0–7) | 0.0374 | — | — |
| BVAS v3 > 0, n (%) | 7 (35.0) | 2 (8.3) | 0.028 | — | — |
| VDI | 3 (2–4) | 3 (2–4) | NS | — | — |
| ESR, mm/h | 21 (9–35) | 22.5 (9–55) | NS | — | — |
| CRP, mg/L | 1.8 (0.3–7.8) | 1.9 (0.5–24.5) | NS | — | — |
| Immunosuppressive agents, n (%) | 11 (55.0) | 13 (54.2) | NS | — | — |
| DMARDs, n (%) | 11 (100) | 12 (92.3) | NS | ||
| Rituximab, n (%) | 0 (0) | 1 (7.7) | NS | ||
| Oral glucocorticoids, n (%) | 10 (50.0) | 13 (54.2) | NS | — | — |
| Oral glucocorticoids, mg/d | 1.25 (0–7.5) | 3.25 (0–5) | NS | ||
| Oral antibiotic (cotrimoxazole), n (%) | 2 (10.0) | 0 (0) | NS | — | — |
| Nasal steroid, n (%) | 6 (30.0) | 1 (4.2) | 0.0353 | 16 (59.2) | 0.047 |
| Local antibiotic, n (%) | 4 (20.0) | — | — | — | — |
| Nasal douche, n (%) | 11 (55.0) | — | — | 4 (14.8) | 0.0035 |
| Moisturizing ointments, n (%) | 6 (30.0) | 1 (4.2) | 0.0353 | 3 (11.1) | NS |
Values in bold mean that they are statistically significant (p < 0.05).
All data are presented as median and IQR, if not otherwise specified.
BVAS v3, Birmingham Vasculitis Activity Score version 3; ESR, erythrocytes sedimentation rate; CRP, C-reactive protein; DMARDs, disease-modifying antirheumatic drugs; MPO, myeloperoxidase; NS, nonsignificant; PR3, proteinase 3.